Abstract
Uncontrolled severe asthma is accompanied by exacerbations despite maximal therapy. In the last few decades, new biological drugs have been developed.
These drugs directly interfere with the pathogenesis of the disease at the molecular-cellular level, and this treatment has brought a major breakthrough in the treatment of severe asthma. Tezepelumab is another biologic intended for the T2-high endotype, but at the same time with the potential to act on the T2-low endotype.
Unlike the other biologics available so far, it is able to suppress all three biomarkers of the T2-high phenotype pathway (peripheral blood eosinophils, total IgE and FeNO), and has an effect on bronchial hyperresponsiveness and airway remodeling, while also being able to reduce exacerbations. The studies conducted so far in a large patient population show a very good safety profile of this drug.
It will therefore be a promising new treatment for severe asthma.